Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Intrapharm Laboratories Limited, The Courtyard Barns, Choke Lane, Cookham Dean, Maidenhead, Berkshire, SL6 6PT, UNITED KINGDOM
Pharmacotherapeutic group: mucolytic
ATC code: R05CB03
(R: respiratory system)
Carbocisteine is a mucolytic agent that modifies mucous secretions. It acts during the mucous gel phase, most likely by breaking up the disulfide bonds in glycoproteins, thereby favouring expectoration.
After oral administration, carbocisteine is quickly absorbed; maximum plasma concentration is reached in two hours.
Its bioavailability is low, less than 10% of the administered dose, most likely via intraluminal metabolism with a significant hepatic first pass effect.
Elimination half-life is about 2 hours. Carbocisteine and its metabolites are excreted primarily through the kidneys.
Tests in a wide range of animal species have revealed no significant toxicity. Serious adverse events associated with the use of carbocisteine have not been reported. Even symptomatic adverse events are very rare.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
